TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3631792

Group type: EXPERIMENTAL
Intervention: Intervention patients with previous test results displayed
Number of subjects: 4683

Group type: COMPARATOR
Intervention: Control patients without previous test results displayed
Number of subjects: 4683
Study: 29352722

Group type: EXPERIMENTAL
Intervention: Mucuna pruriens (MP) powder
Number of subjects: 14

Group type: COMPARATOR
Intervention: Marketed levodopa/carbidopa (LD/CD)
Number of subjects: 14
Study: 27446616

Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise (90% Maximal Power Output) at 20 min after acquisition (EX90)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise (90% Maximal Power Output) at 1 h after acquisition (EX90+1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise (90% Maximal Power Output) at 2 h after acquisition (EX90+2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (rested) (CON)
Number of subjects: 48
Study: 25686147

Group type: EXPERIMENTAL
Intervention: Oral insertion
Number of subjects: 63

Group type: COMPARATOR
Intervention: Nasal insertion
Number of subjects: 63
Study: 23661528

Group type: EXPERIMENTAL
Intervention: Food supplement containing forskolin, rutin, and vitamins B1 and B2 for 30 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 21034946

Group type: EXPERIMENTAL
Intervention: Intracorporeal purse string suture around the internal inguinal ring (IIR) using 2 needle holders
Number of subjects: 150

Group type: COMPARATOR
Intervention: Extracorporeal knotting using a Reverdin needle (RN)
Number of subjects: 150
Study: 18579283

Group type: COMPARATOR
Intervention: Conventional conservative preparation (G1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Modified preparation with cavosurface bevel (G2)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Overall restorations
Number of subjects: 32
Study: 16636486

Group type: EXPERIMENTAL
Intervention: Tirofiban (10 mg/kg bolus followed by infusion of 0.15 mg . kg(‐1) . min (‐1) until total dose reached 12.5 mg)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control group (standard PCI)
Number of subjects: 217
Study: 12006956

Group type: EXPERIMENTAL
Intervention: L-arginine supplementation (1.5 mmol/kg per day)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 10692751

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 122

Group type: COMPARATOR
Intervention: Captopril 25 mg
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 7473451

Group type: EXPERIMENTAL
Intervention: 0.6 mg/d of conjugated equine estrogen (CEE) cyclically (n = 15)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 50 micrograms/d of transdermal estradiol (E2) cyclically (n = 17)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.6 mg/d of CEE continuously (n = 17)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of CEE and 2.5 mg/d of MPA continuously (n = 19)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Treatment-free control group (n = 22)
Number of subjects: 90
Study: 1685182

Group type: EXPERIMENTAL
Intervention: Early nasoduodenal feeding (from the first postoperative day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (feeding started on the fourth postoperative day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Early nasoduodenal feeding
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 6315329

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily for two weeks)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Nifedipine (4 X 10 mg daily for four weeks)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg daily for two weeks)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Nifedipine alone (4 X 10 mg daily)
Number of subjects: 7
Study: 31626571

Group type: EXPERIMENTAL
Intervention: Stage-adapted first-line treatment (radiotherapy alone, chemotherapy alone, or combined-modality approaches)
Number of subjects: 471
Study: 30275228

Group type: EXPERIMENTAL
Intervention: Intraperitoneal paclitaxel followed by paclitaxel, cisplatin, and S‐1 (PCS) chemotherapy
Number of subjects: 17
Study: 27484875

Group type: EXPERIMENTAL
Intervention: Increased femoral offset
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Combined femoral and acetabular offset
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Decreased acetabular offset
Number of subjects: 359
Study: 25549086

Group type: EXPERIMENTAL
Intervention: Artemisinin-naphthoquine (three daily doses)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (six doses over 3 days)
Number of subjects: 267
Study: 22332205

Group type: EXPERIMENTAL
Intervention: High ω‐3 intake (≥0.20 g/d)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Low ω‐3 intake (<0.20 g/d)
Number of subjects: 357
Study: 19996989

Group type: EXPERIMENTAL
Intervention: Exercise program (Sex Hormones and Physical Exercise study)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 18713761

Group type: EXPERIMENTAL
Intervention: Mirtazapine 30 mg
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 15972582

Group type: EXPERIMENTAL
Intervention: Once-monthly oral ibandronate 150 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Once-monthly oral ibandronate 100 mg
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 12929899

Group type: EXPERIMENTAL
Intervention: CATCH classroom component
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CATCH food service component
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CATCH physical education (PE) component
Number of subjects: 0
Study: 10720074

Group type: EXPERIMENTAL
Intervention: Low-insulin-hypoglycemic condition (insulin infusion at 1.5 mU/min x kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-insulin-hypoglycemic condition (insulin infusion at 15.0 mU/min x kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-insulin-euglycemic condition (insulin infusion at 1.5 mU/min x kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-insulin-euglycemic condition (insulin infusion at 15.0 mU/min x kg)
Number of subjects: 30
Study: 8784650

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 21
Study: 1611649

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg QD
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg QD
Number of subjects: 217

Group type: COMPARATOR
Intervention: Pravastatin 10 mg QD
Number of subjects: 217
Study: 6140343

Group type: EXPERIMENTAL
Intervention: Oestradiol and testosterone implants
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 30561059

Group type: EXPERIMENTAL
Intervention: Telmisartan 2 mg/kg q24 PO
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 30195826

Group type: EXPERIMENTAL
Intervention: Patient-centered decision aid (DA)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard education (SE)
Number of subjects: 98
Study: 26582633

Group type: EXPERIMENTAL
Intervention: Low-load resistance exercise (15-20 RM)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Moderate-load resistance exercise (10-12 RM)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High-load resistance exercise (6-8 RM)
Number of subjects: 21
Study: 24862255

Group type: EXPERIMENTAL
Intervention: Sodium valproate (800mg/day)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 22856192

Group type: EXPERIMENTAL
Intervention: Liposome-associated recombinant SEF21
Number of subjects: 0
Study: 20099352

Group type: EXPERIMENTAL
Intervention: Gadodiamide-enhanced MRA (0.1 mmol/kg)
Number of subjects: 395
Study: 18191732

Group type: EXPERIMENTAL
Intervention: Intravenous iron (200 mg weekly until ferritin >500 ng/ml, 200 mg monthly thereafter)
Number of subjects: 35
Study: 16393724

Group type: EXPERIMENTAL
Intervention: Nebulized beta2-agonist
Number of subjects: 333

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: 3-MRET (three-minute respiratory exercise test)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 333
Study: 12860899

Group type: EXPERIMENTAL
Intervention: CRT-on (n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: CRT-off (n=25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CRT-on
Number of subjects: 50

Group type: COMPARATOR
Intervention: CRT-off
Number of subjects: 50
Study: 9869598

Group type: EXPERIMENTAL
Intervention: Infliximab (5-20 mg/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8703705

Group type: EXPERIMENTAL
Intervention: Oral calcium loading test
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral furosemide
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 120
Study: 2057975

Group type: EXPERIMENTAL
Intervention: Headache in patients with acute cerebral or retinal ischemia
Number of subjects: 3126

Group type: EXPERIMENTAL
Intervention: Headache presence
Number of subjects: 3126

Group type: EXPERIMENTAL
Intervention: Headache in patients with monocular visual symptoms
Number of subjects: 3126

Group type: EXPERIMENTAL
Intervention: Headache occurrence related to infarct type
Number of subjects: 3126

Group type: EXPERIMENTAL
Intervention: Headache and heart disease
Number of subjects: 3126

Group type: EXPERIMENTAL
Intervention: Headache and ischemic symptoms
Number of subjects: 3126
Study: 6536520

Group type: EXPERIMENTAL
Intervention: Polyethylene catheters
Number of subjects: 52

Group type: COMPARATOR
Intervention: Silicone catheters
Number of subjects: 52

Group type: COMPARATOR
Intervention: Polyurethane catheters
Number of subjects: 52
Study: 31274739

Group type: EXPERIMENTAL
Intervention: Chemical stimulation of the cornea
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mechanical stimulation of the cornea
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Corneal stimulation (mechanical and chemical)
Number of subjects: 15
Study: 29558490

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training with maslinic acid (WBVT/MA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Whole-body vibration training with placebo (WBVT/P)
Number of subjects: 26
Study: 26856618

Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone (20mg daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 24708224

Group type: EXPERIMENTAL
Intervention: Whey isolate (WI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gluten (GLU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cod (COD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Casein
Number of subjects: 0
Study: 23006411

Group type: COMPARATOR
Intervention: Combination exercise training
Number of subjects: 64

Group type: COMPARATOR
Intervention: Resistance exercise training
Number of subjects: 64
Study: 20298820

Group type: EXPERIMENTAL
Intervention: Partial body weight-supported treadmill training (PBWSTT) for 9 weeks, twice weekly.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Overground walking practice for 9 weeks, twice weekly.
Number of subjects: 34
Study: 17381930

Group type: EXPERIMENTAL
Intervention: Price discounts
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Nutrition education
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Combination of price discounts and nutrition education
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 97
Study: 17390928

Group type: EXPERIMENTAL
Intervention: Cath‐Assist device; designed to facilitate female urethral catheterization by exposing the vulvar vestibule, isolating the urethral opening, and blocking the entrance to the vagina.
Number of subjects: 1
Study: 15118483

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 11731813

Group type: EXPERIMENTAL
Intervention: 17D yellow fever vaccine administered at 6 months
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: 17D yellow fever vaccine administered at 9 months
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 420
Study: 9248050

Group type: EXPERIMENTAL
Intervention: Actors' self-presentation influenced by another person's self-description; observed positivity matched the other's positivity.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Actors' metaperceptions connected to their general beliefs about themselves.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blindness effect driven primarily by actors low in self-esteem.
Number of subjects: 0
Study: 8518900

Group type: EXPERIMENTAL
Intervention: One-layer anastomosis
Number of subjects: 107

Group type: COMPARATOR
Intervention: Two-layer anastomosis
Number of subjects: 107
Study: 3327637

Group type: EXPERIMENTAL
Intervention: Prophylactic systemic antibiotics
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no antibiotic prophylaxis)
Number of subjects: 71
Study: 31283053

Group type: EXPERIMENTAL
Intervention: Oxytocin (64 IU)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 28185672

Group type: EXPERIMENTAL
Intervention: Cariprazine (mean daily dose 4.2 mg)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Risperidone (mean daily dose 3.8 mg)
Number of subjects: 461
Study: 26466996

Group type: EXPERIMENTAL
Intervention: Radial artery (RA) grafts
Number of subjects: 200

Group type: COMPARATOR
Intervention: Saphenous vein graft (SVG)
Number of subjects: 200
Study: 23788362

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21319157

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 3013

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 3013
Study: 19670818

Group type: EXPERIMENTAL
Intervention: Vitaprost plus
Number of subjects: 0
Study: 17928726

Group type: EXPERIMENTAL
Intervention: IgY‐GP gel subgingivally applied with subgingival scaling and root planing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Subgingival scaling and root planing alone (Control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: IgY‐GP gel
Number of subjects: 10
Study: 15764039

Group type: EXPERIMENTAL
Intervention: UVA/UVB phototherapy (Group I)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: UVA/UVB + topical corticosteroids (Group II)
Number of subjects: 31
Study: 12014489

Group type: EXPERIMENTAL
Intervention: Coloured overlays
Number of subjects: 233
Study: 9696226

Group type: EXPERIMENTAL
Intervention: Sperm motility parameters (assessed with computer‐aided sperm analysis)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Percent normal morphology (determined with strict criteria)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Samples achieving > or =50% fertilization
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Samples achieving pregnancy
Number of subjects: 150
Study: 7805972

Group type: COMPARATOR
Intervention: Ritodrine tablets
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sustained-release capsules
Number of subjects: 32
Study: 2683423

Group type: EXPERIMENTAL
Intervention: HDL-rich serum fractions (HDLF)
Number of subjects: 35
Study: 31217069

Group type: EXPERIMENTAL
Intervention: BRiMS intervention (13-week education and exercise programme) plus usual care
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 56
Study: 28571563

Group type: EXPERIMENTAL
Intervention: MFFP intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Advice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 0
Study: 25380107

Group type: EXPERIMENTAL
Intervention: 3% or 23.4% hypertonic saline (HTS) as bolus therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: 20% mannitol
Number of subjects: 25
Study: 23511556

Group type: EXPERIMENTAL
Intervention: Lentivirus-mediated AIB1 knockdown
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: AIB1 overexpression
Number of subjects: 146
Study: 21618480

Group type: EXPERIMENTAL
Intervention: Avotermin 500 ng per 100 µl per linear cm of wound margin, administered by intradermal injection to the groin and distal wound margins of one leg.
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo, administered to the other leg.
Number of subjects: 156
Study: 19081393

Group type: EXPERIMENTAL
Intervention: Barber-based intervention (BP check with each haircut and encouragement for medical referral)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No active intervention (control group)
Number of subjects: 0
Study: 16401443

Group type: EXPERIMENTAL
Intervention: Long-term Tai Chi training (1 to 3 years)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Short-term Tai Chi training (3 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No Tai Chi training (nonpractitioners)
Number of subjects: 48
Study: 15865549

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (4 g/0.5 g q8h)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Ampicillin/sulbactam (2 g/1 g q6h)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 314

Group type: COMPARATOR
Intervention: Ampicillin/sulbactam
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam and Ampicillin/sulbactam
Number of subjects: 314
Study: 11206417

Group type: EXPERIMENTAL
Intervention: Insulin (1 mU/kg/min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Insulin (2 mU/kg/min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (5.6 mmol/l, 11.1 mmol/l, 16.7 mmol/l)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Insulin + Hyperglycaemia with somatostatin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Basal conditions (no somatostatin)
Number of subjects: 9
Study: 9205656

Group type: EXPERIMENTAL
Intervention: Saliva Orthana (mucin-containing oral spray)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (mucin-free spray)
Number of subjects: 35
Study: 8440931

Group type: EXPERIMENTAL
Intervention: D protein vaccine (500 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: D protein vaccine
Number of subjects: 0
Study: 3619219

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30907203

Group type: EXPERIMENTAL
Intervention: Gallbladder stone disease cohort
Number of subjects: 9362

Group type: EXPERIMENTAL
Intervention: Gallbladder stone disease men with cholecystectomy
Number of subjects: 9362
Study: 28350401

Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS) pre-treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PBO) pre-treatment
Number of subjects: 8
Study: 26143536

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 22767151

Group type: EXPERIMENTAL
Intervention: 8 mg of TER
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 21148518

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulphadoxine-pyrimethamine (SP)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: HIV-positive women
Number of subjects: 270
Study: 18650629

Group type: EXPERIMENTAL
Intervention: Multimedia-based information program (MM-IP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard informed consent process
Number of subjects: 80
Study: 17050202

Group type: EXPERIMENTAL
Intervention: nested-PCR assay
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: RQ-PCR analysis
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: antigenemia assay
Number of subjects: 72

Group type: COMPARATOR
Intervention: antithymocyte globulin conditioning
Number of subjects: 72
Study: 15344541

Group type: EXPERIMENTAL
Intervention: Lansoprazole (LPZ) 30 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lansoprazole (LPZ) 15 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Famotidine (FAM) 40 mg/day
Number of subjects: 0
Study: 11002217

Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion (HAI) with 5‐FU at 600 mg/m(2)/day for 2 consecutive days per week and oral UFT at 400 mg/day for 5‐7 days per week, repeated 10 times (Group A)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Oral UFT at 400 mg/day for 6 months (Group B)
Number of subjects: 58
Study: 9021437

Group type: EXPERIMENTAL
Intervention: Sustained release theophylline (SR-T)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Oral fenoterol 2.5 mg 3 times daily
Number of subjects: 21
Study: 7940144

Group type: EXPERIMENTAL
Intervention: Timolol 0.25% eyedrops (during treatment)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Timolol withdrawn (off treatment)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ocular normotensive control
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ocular hypertensives
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 26
Study: 3064818

Group type: EXPERIMENTAL
Intervention: Fresh human milk or fortified human milk with protein intake of 2.1 to 3.3 g/kg/day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Protein intake on the 21st day of life
Number of subjects: 33
Study: 31600531

Group type: EXPERIMENTAL
Intervention: Large BCCs
Number of subjects: 248

Group type: COMPARATOR
Intervention: Mohs micrographic surgery
Number of subjects: 248
Study: 31246714

Group type: EXPERIMENTAL
Intervention: Sleep Extension (SE)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sleep Restriction (SR)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal Sleep (NS)
Number of subjects: 9
Study: 28323846

Group type: EXPERIMENTAL
Intervention: Intervention group (self-management program)
Number of subjects: 47
Study: 26232904

Group type: EXPERIMENTAL
Intervention: Encouragement message
Number of subjects: 6021

Group type: EXPERIMENTAL
Intervention: Tailored message about low-cost vaccination
Number of subjects: 6021

Group type: COMPARATOR
Intervention: General education
Number of subjects: 6021

Group type: COMPARATOR
Intervention: Education tailored to reason for non-vaccination
Number of subjects: 6021